FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912974250> ?p ?o ?g. }

• W2912974250 endingPage "72" @default.
• W2912974250 startingPage "62" @default.
• W2912974250 abstract "Background: A recent meta-analysis affirmed the benefit of medicinal cannabis for chronic neuropathic pain, a disabling and difficult-to-treat condition. As medicinal cannabis use is becoming increasingly prevalent among Americans, an exploration of its economic feasibility is warranted. We present this cost-effectiveness analysis of adjunctive cannabis pharmacotherapy for chronic peripheral neuropathy. Materials and Methods: A published Markov model comparing conventional therapies for painful diabetic neuropathy was modified to include arms for augmenting first-line, second-line (if first-line failed), or third-line (if first- and second-line failed) therapies with smoked cannabis. Microsimulation of 1,000,000 patients compared the cost (2017 U.S. dollars) and effectiveness (quality-adjusted life years [QALYs]) of usual care with and without adjunctive cannabis using a composite of third-party and out-of-pocket costs. Model efficacy inputs for cannabis were adapted from clinical trial data. Adverse event rates were derived from a prospective study of cannabis for chronic noncancer pain and applied to probability inputs for conventional therapies. Cannabis cost was derived from retail market pricing. Parameter uncertainty was addressed with one-way and probabilistic sensitivity analysis. Results: Adding cannabis to first-line therapy was incrementally less effective and costlier than adding cannabis to second-line and third-line therapies. Third-line adjunctive cannabis was subject to extended dominance, that is, the second-line strategy was more effective with a more favorable incremental cost-effectiveness ratio of $48,594 per QALY gained, and therefore, third-line adjunctive cannabis was not as cost-effective. At a modest willingness-to-pay threshold of $100,000/QALY gained, second-line adjunctive cannabis was the strategy most likely to be cost-effective. Conclusion: As recently proposed willingness-to-pay thresholds for the United States health marketplace range from $110,000 to $300,000 per QALY, cannabis appears cost-effective when augmenting second-line treatment for painful neuropathy. Further research is warranted to explore the long-term benefit of smoked cannabis and standardization of its dosing for chronic neuropathic pain." @default.
• W2912974250 created "2019-02-21" @default.
• W2912974250 creator A5014736796 @default.
• W2912974250 creator A5017049966 @default.
• W2912974250 creator A5025523388 @default.
• W2912974250 creator A5026920489 @default.
• W2912974250 creator A5038978045 @default.
• W2912974250 creator A5040325066 @default.
• W2912974250 creator A5045020425 @default.
• W2912974250 creator A5045032519 @default.
• W2912974250 creator A5049167907 @default.
• W2912974250 creator A5061503842 @default.
• W2912974250 creator A5064099533 @default.
• W2912974250 date "2019-03-01" @default.
• W2912974250 modified "2023-10-06" @default.
• W2912974250 title "A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain" @default.
• W2912974250 cites W1409549508 @default.
• W2912974250 cites W1537598136 @default.
• W2912974250 cites W1978224806 @default.
• W2912974250 cites W1980890985 @default.
• W2912974250 cites W1987613482 @default.
• W2912974250 cites W1988364618 @default.
• W2912974250 cites W1993424123 @default.
• W2912974250 cites W1993981100 @default.
• W2912974250 cites W1996838131 @default.
• W2912974250 cites W2012877562 @default.
• W2912974250 cites W2022936510 @default.
• W2912974250 cites W2027897070 @default.
• W2912974250 cites W2031114852 @default.
• W2912974250 cites W2033158772 @default.
• W2912974250 cites W2034456357 @default.
• W2912974250 cites W2039824535 @default.
• W2912974250 cites W2048776101 @default.
• W2912974250 cites W2049660996 @default.
• W2912974250 cites W2051397464 @default.
• W2912974250 cites W2055142129 @default.
• W2912974250 cites W2056120043 @default.
• W2912974250 cites W2056588555 @default.
• W2912974250 cites W2058056848 @default.
• W2912974250 cites W2060919607 @default.
• W2912974250 cites W2063273112 @default.
• W2912974250 cites W2066497328 @default.
• W2912974250 cites W2066712833 @default.
• W2912974250 cites W2076964900 @default.
• W2912974250 cites W2081629704 @default.
• W2912974250 cites W2082851416 @default.
• W2912974250 cites W2092998525 @default.
• W2912974250 cites W2093849709 @default.
• W2912974250 cites W2099211847 @default.
• W2912974250 cites W2099304023 @default.
• W2912974250 cites W2102522185 @default.
• W2912974250 cites W2102938408 @default.
• W2912974250 cites W2109927649 @default.
• W2912974250 cites W2113749043 @default.
• W2912974250 cites W2114826780 @default.
• W2912974250 cites W2117419474 @default.
• W2912974250 cites W2120142285 @default.
• W2912974250 cites W2122063286 @default.
• W2912974250 cites W2123945136 @default.
• W2912974250 cites W2133895281 @default.
• W2912974250 cites W2134047636 @default.
• W2912974250 cites W2135015648 @default.
• W2912974250 cites W2139407741 @default.
• W2912974250 cites W2147680588 @default.
• W2912974250 cites W2161693441 @default.
• W2912974250 cites W2167149788 @default.
• W2912974250 cites W2183867796 @default.
• W2912974250 cites W2206489433 @default.
• W2912974250 cites W2235318197 @default.
• W2912974250 cites W2252967586 @default.
• W2912974250 cites W2336016151 @default.
• W2912974250 cites W2475610676 @default.
• W2912974250 cites W2519603001 @default.
• W2912974250 cites W2561727131 @default.
• W2912974250 cites W257547705 @default.
• W2912974250 cites W2616217127 @default.
• W2912974250 cites W2619558297 @default.
• W2912974250 cites W2751676254 @default.
• W2912974250 cites W2766495806 @default.
• W2912974250 doi "https://doi.org/10.1089/can.2018.0027" @default.
• W2912974250 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6446169" @default.
• W2912974250 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30944870" @default.
• W2912974250 hasPublicationYear "2019" @default.
• W2912974250 type Work @default.
• W2912974250 sameAs 2912974250 @default.
• W2912974250 citedByCount "9" @default.
• W2912974250 countsByYear W29129742502020 @default.
• W2912974250 countsByYear W29129742502021 @default.
• W2912974250 countsByYear W29129742502022 @default.
• W2912974250 countsByYear W29129742502023 @default.
• W2912974250 crossrefType "journal-article" @default.
• W2912974250 hasAuthorship W2912974250A5014736796 @default.
• W2912974250 hasAuthorship W2912974250A5017049966 @default.
• W2912974250 hasAuthorship W2912974250A5025523388 @default.
• W2912974250 hasAuthorship W2912974250A5026920489 @default.
• W2912974250 hasAuthorship W2912974250A5038978045 @default.
• W2912974250 hasAuthorship W2912974250A5040325066 @default.
• W2912974250 hasAuthorship W2912974250A5045020425 @default.

• next